NasdaqGS - Delayed Quote USD
scPharmaceuticals Inc. (SCPH)
At close: October 18 at 4:00 PM EDT
After hours: October 18 at 5:45 PM EDT
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 5 | 6 |
| Avg. Estimate | -0.3 | -0.27 | -1.35 | -0.73 |
| Low Estimate | -0.33 | -0.34 | -1.47 | -1.1 |
| High Estimate | -0.28 | -0.24 | -1.29 | -0.42 |
| Year Ago EPS | -0.41 | -0.35 | -1.42 | -1.35 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | 10.8M | 14.54M | 39.4M | 96.55M |
| Low Estimate | 10.15M | 13M | 37.4M | 82.5M |
| High Estimate | 12.1M | 16.4M | 42.7M | 126.9M |
| Year Ago Sales | 3.8M | 6.1M | 13.59M | 39.4M |
| Sales Growth (year/est) | 184.50% | 138.50% | 189.90% | 145.10% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.36 | -0.42 | -0.44 | -0.41 |
| EPS Actual | -0.41 | -0.35 | -0.36 | -0.44 |
| Difference | -0.05 | 0.07 | 0.08 | -0.03 |
| Surprise % | -13.90% | 16.70% | 18.20% | -7.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.3 | -0.27 | -1.35 | -0.73 |
| 7 Days Ago | -0.3 | -0.27 | -1.35 | -0.73 |
| 30 Days Ago | -0.3 | -0.27 | -1.35 | -0.73 |
| 60 Days Ago | -0.3 | -0.27 | -1.35 | -0.73 |
| 90 Days Ago | -0.38 | -0.32 | -1.46 | -0.78 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | SCPH | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 26.80% | -- | -- | 3.70% |
| Next Qtr. | 22.90% | -- | -- | 7.90% |
| Current Year | 4.90% | -- | -- | 2.50% |
| Next Year | 45.90% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.88% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/19/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/15/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/14/2024 |
| Initiated | Craig-Hallum: Buy | 9/7/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/11/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/2/2023 |
Related Tickers
VIGL Vigil Neuroscience, Inc.
3.9600
-0.75%
VRCA Verrica Pharmaceuticals Inc.
1.6000
+9.59%
MIST Milestone Pharmaceuticals Inc.
1.4900
+1.36%
IKT Inhibikase Therapeutics, Inc.
2.1300
-9.36%
SWTX SpringWorks Therapeutics, Inc.
30.97
+0.62%
TRVI Trevi Therapeutics, Inc.
3.1200
0.00%
ATXS Astria Therapeutics, Inc.
11.46
-2.55%
SNDX Syndax Pharmaceuticals, Inc.
19.71
-0.90%
XNCR Xencor, Inc.
21.78
+1.97%
ACRV Acrivon Therapeutics, Inc.
8.25
+4.83%